文献速递介入腹部DSA

放射段切除术:早期肝细胞癌的潜在治愈性治疗

Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma.
PubMed 文献 · Radiology · 2018-04-24

这项回顾性研究纳入70例不适合经皮消融的单发≤5 cm肝细胞癌患者,2003至2016年间接受剂量>190 Gy的放射段切除术。按EASL标准90%缓解、59%完全缓解;中位总生存6.7年,5年生存率57%;肿瘤≤3 cm者5年生存率75%,显著优于>3 cm者。作者认为其缓解率、肿瘤控制和生存与治愈性治疗相当。

要点

  • 单发≤5 cm、肝功能保留且不适合经皮消融的早期肝细胞癌,放射段切除术(剂量>190 Gy)可获得与治愈性治疗相当的结局。
  • 按EASL标准缓解率90%、完全缓解59%;按WHO标准缓解率71%、完全缓解16%。
  • 中位总生存6.7年,5年生存率57%;肿瘤≤3 cm者5年生存率75%,显著优于>3 cm者的相应生存(P = .026)。

核心结论

  • 对经选择的、肝功能保留的早期肝细胞癌患者,放射段切除术提供的缓解率、肿瘤控制和生存结局与治愈性治疗相当。

研究设计与样本

  • 回顾性研究,纳入70例单发≤5 cm、不适合经皮消融的肝细胞癌患者(中位年龄71岁,范围22-96岁),2003至2016年间接受剂量>190 Gy的放射段切除术;排除后续接受治愈性肝移植者以消除影响生存的混杂因素;采用Kaplan-Meier法按EASL和WHO指南评估影像学缓解、至进展时间和中位总生存。

诊断标准与关键数值

  • 按EASL标准63例(90%)缓解,其中41例(59%)完全缓解;按WHO标准50例(71%)缓解,其中11例(16%)完全缓解;6个月缓解率按EASL和WHO标准分别为86%和49%;中位至进展时间2.4年(95%CI:2.1,5.7),72%患者5年内无靶病灶进展;中位总生存6.7年(95%CI:3.1,6.7),1、3、5年生存概率分别为98%、66%、57%;基线肿瘤≤3 cm者(n=45)1、3、5年生存概率分别为100%、82%、75%,显著长于>3 cm者(P = .026)。

临床应用与阅片要点

  • 作者认为,对经选择的、肝功能保留的早期肝细胞癌患者,放射段切除术的缓解率、肿瘤控制和生存结局与治愈性治疗相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

Purpose To report long-term outcomes of radiation segmentectomy (RS) for early hepatocellular carcinoma (HCC). The authors hypothesized that outcomes are comparable to curative treatments for patients with solitary HCC less than or equal to 5 cm and preserved liver function. Materials and Methods This retrospective study included 70 patients (median age, 71 years; range, 22-96 years) with solitary HCC less than or equal to 5 cm not amenable to percutaneous ablation who underwent RS (dose of >190 Gy) between 2003 and 2016. Patients who underwent subsequent curative liver transplantation were excluded to eliminate this confounding variable affecting survival. Radiologic response of time to progression and median overall survival were estimated by using the Kaplan-Meier method per the guidelines of the European Association for the Study of the Liver (EASL) and the World Health Organization (WHO). Results Seventy patients were treated with RS over 14 years. Sixty-three patients (90%) showed response by using EASL criteria, of which 41 (59%) showed complete response. Fifty patients (71%) achieved response by using WHO criteria, of which 11 (16%) achieved complete response. Response rates at 6 months were 86% and 49% by using EASL and WHO criteria, respectively. Median time to progression was 2.4 years (95% confidence interval: 2.1, 5.7), with 72% of patients having no target lesion progression at 5 years. Median overall survival was 6.7 years (95% confidence interval: 3.1, 6.7); survival probability at 1, 3, and 5 years was 98%, 66%, and 57%, respectively. Overall survival probability at 1, 3, and 5 years was 100%, 82%, and 75%, respectively, in patients with baseline tumor size less than or equal to 3 cm (n = 45) and was significantly longer than in patients with tumors greater than 3 cm (P = .026). Conclusion RS provides response rates, tumor control, and survival outcomes comparable to curative-intent treatments for selected patients with early-stage HCC who have preserved liver function. © RSNA, 2018 Online supplemental material is available for this article.

来源:Radiology,查看原文。版权归原作者所有。

引用

  1. Lewandowski RJ, Gabr A, Abouchaleh N, et al. Radiation Segmentectomy: Potential Curative Therapy for Early Hepatocellular Carcinoma. Radiology. 2018. PMID: 29688155. doi:10.1148/radiol.2018171768

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。